University Health Network, Toronto: Ovarian Neoplasms trials
The registry lists 22 Ovarian Neoplasms studies with University Health Network, Toronto as lead sponsor. 6 are open to participants now and 0 have results posted.
Phase 1 5Phase 2 8Phase 3 1No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian CancerNot yet recruitingNCT07286162Phase 3
- Feasibility of CALM in Patients With Ovarian CancerRecruitingNCT06459271Not applicable
- Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)RecruitingNCT05403177
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
- Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching HostRecruitingNCT02732860
- Erdafitinib in Metastatic Steroid-cell Ovarian CancerCompletedNCT06328491Not applicable
- Luspatercept in Metastatic AGCT of the OvaryCompletedNCT06254781Not applicable
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine CancerActive, not recruitingNCT06107868Phase 1
- Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicable
- 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)CompletedNCT03811899Not applicable
- A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian CancerCompletedNCT03081702Phase 1/2
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsActive, not recruitingNCT02869217Phase 1
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
- Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian CancerActive, not recruitingNCT02494791Not applicable
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT02489006Phase 2
- Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.TerminatedNCT02341118
- A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
- Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel ObstructionTerminatedNCT01083537Phase 1/2
- Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian CancerTerminatedNCT00889733Phase 1/2
- UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00072267Phase 2